


Cell Line Designation	LIM1899
CellBank Catalogue No.	CBA-0163
Lot Number	01630810E
Passage Number	+8
Total Cell Number	3.1x 10 ⁶ cells
Expected Cell Viability	95%
Brief Description	Columnar cell adenocarcinoma of the colon
Organism	Human (<i>Homo Sapiens</i>)
Tissue	Colon
Growth Properties	Adherent
Morphology	Epithelial. Cells are small rounded and grow in clusters.
Image	 <p>CellBank Australia Number: CBA-0163 Cell Line Designation: LIM1899</p> <p>© CellBank Australia (100x magnification)</p>
Growth Medium	RPMI1640 (with 2mM L-Glutamine +25mM Hepes) +10%FCS, Insulin 0.6µg/ml, Hydrocortisone 1µg/ml, 1-Thioglycerol 10µM
Subcultivation Ratio	Split sub confluent flasks (70-80%), optimal split ratio 1:8 using 0.05%Trypsin /EDTA at 37°C for 5 minutes. Seeding density 1x10 ⁴ cells/cm ²
Establishing and Maintaining your Culture	Cells maintained at 37°C and 5% CO ₂ . LIM1899 requires growth medium to be changed 3 times each week. Refer to Technical & Customer Service Information pamphlet for further information
Cryoprotectant Medium	10% DMSO + 90% FCS

Biosafety level	Cell line of human origin. CellBank Australia recommends that cell lines be handled at category PC-2* containment level. *AS/NZS 2243.3:2010
Use Restrictions	These cells are distributed for research purposes only - refer to the Material Transfer Agreement (MTA).
Safety Precaution	Where cell lines are shipped as frozen ampoules there is a small risk that the ampoule may be pressurised, due to the expansion of trapped liquid nitrogen and could explode on warming. It is recommended that persons handling ampoules of frozen cells wear appropriate personal protective equipment including laboratory coat, insulated gloves and a full protective face shield.
Handling Procedure for Frozen Cells	Upon receipt, frozen ampoules should be transferred directly to liquid nitrogen storage without delay, if not to be used immediately. Storage at -80°C may result in loss of viability. Remove protective cryoflex layer around the ampoule prior to thawing. A precentrifugation step to remove the cryoprotectant after thawing is necessary for this cell line.
Additional Information	Sporadic CRC, mutated beta-catenin and K-Ras, A33 +ve
Depositor	Professor Tony Burgess Ludwig Institute for Cancer Research Ltd, Melbourne –Australia
References	Zhang H. <i>et al.</i> Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf. <i>Int.J.Cancer</i> 2009 July15; 125(2):297-307 Andrew S.M <i>et al.</i> Tumour localization by combinations of monoclonal antibodies in a new human colon carcinoma cell line. <i>Cancer Research</i> 1990 September 1; 50(17):5225-5230
CellBank Warranty	While CellBank Australia uses reasonable efforts to include accurate and up-to date information on this product sheet, CellBank Australia makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. CellBank Australia does not warrant that such information has been confirmed to be accurate.
Disclaimers	This product is sent with the condition that you are responsible for its safe storage, handling, and use. CellBank Australia is not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to insure authenticity and reliability of strains on deposit, CellBank Australia is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the MTA for further details regarding the use of this product. The MTA is also available on our Web site at www.cellbankaustralia.com